Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)

Pieris Pharmaceuticals (NASDAQ:PIRS) Second Quarter 2024 Results

Key Financial Results

• Net loss: US$3.59m (down by 190% from US$3.98m profit in 2Q 2023).
• US$2.76 loss per share (down from US$3.63 profit in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pieris Pharmaceuticals shares are up 9.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Pieris Pharmaceuticals (2 can't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.